Dual CSF1R/PI3Kγ blockade simultaneously suppresses STAT3-driven signalling, decreases serum sCD163 pharmacodynamic biomarker levels, and is tolerated up to 800 mg daily with reversible transaminase elevation in phase-I glioma cohorts (45). Here, CSF1R is linked to central nervous system cancer.